Study S001262

The Safety and Efficacy of Acute Subcutaneous Administration of Semaglutide in Non-diabetic Patients With Acute Ischemic Stroke: A Multicentre, Phase 2, Prospective, Randomized, Open-label, Blinded Endpoint Trial

ClinicalTrials.gov record

Registration

Registration: NCT05630586
Acronym: ASSET
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: RECRUITING
Enrollment: 380
Start: 2023-04-12
Primary completion: 2025-09
Lead sponsor: Aarhus University Hospital
Conditions: Acute Ischemic Stroke
Interventions: DRUG:Semaglutide; OTHER:Standard care
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:EUCT number: 2022-501072-25-02

Registered primary outcomes

Modified Ranking Scale [90 (+/- 14) days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.